A new analysis from SRS Acquiom puts into perspective the headline values seen when a company announces a backloaded M&A deal ...

J&J still holds the top deal of the year by value with its $14.6 billion buy of Intra-Cellular in January, but the next four ...

The two most historically deal-conservative Big Pharmas have the most money to play with for a major M&A transaction, ...

Talks between pharma and successive U.K. governments have failed to deliver the market access terms that the industry wants, ...

As major pharmas pull away from the U.K. and the U.S. risks ceding its lead through a national brain drain, the U.K. must ...

MET-097i’s mid-stage performance “bodes well” for Pfizer’s proposed buyout of Metsera, according to BMO Capital Markets, a ...

Without naming Aurinia Pharmaceuticals, the CDER director in a now-deleted LinkedIn post claimed that for lupus nephritis, ...

Pfizer CEO Albert Bourla directly credited the threat of tariffs with leading to the deal, in which the company will offer ...

The agency estimates that about 86% of staff can remain in the event that funding stops, but new drug applications cannot be ...

After parting with 50% of its employees earlier this year, Sutro Biopharma will lay another third of its staff in a ...

Despite tolerability concerns, nomlabofusp's overall efficacy represents a “large win” for Larimar, according to analysts at ...

Already approved in Japan, China and other Asian countries, Crystalys’ dotinurad works to lower serum uric acid levels.